TrialInfection2023

Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial.

Matthew G Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.